These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 17577487)

  • 1. Measurement of malaria vaccine efficacy in phase III trials: report of a WHO consultation.
    Moorthy V; Reed Z; Smith PG;
    Vaccine; 2007 Jul; 25(28):5115-23. PubMed ID: 17577487
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MALVAC 2008: Measures of efficacy of malaria vaccines in phase 2b and phase 3 trials--scientific, regulatory and public health perspectives.
    Moorthy VS; Reed Z; Smith PG;
    Vaccine; 2009 Jan; 27(5):624-8. PubMed ID: 19061928
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and other milestones for human papillomavirus vaccine introduction.
    Pagliusi SR; Teresa Aguado M
    Vaccine; 2004 Dec; 23(5):569-78. PubMed ID: 15630792
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Malaria vaccine trial endpoints - bridging the gaps between trial design, public health and the next generation of vaccines.
    O'Meara WP; Lang T
    Parasite Immunol; 2009 Sep; 31(9):574-81. PubMed ID: 19691560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interpreting challenge data from early phase malaria blood stage vaccine trials.
    Good MF; Miller LH
    Expert Rev Vaccines; 2018 Mar; 17(3):189-196. PubMed ID: 29382292
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Methods for determining vaccine efficacy and effectiveness and the main barriers to developing a fully deployable malaria vaccine.
    Guinovart C; Alonso PL
    Am J Trop Med Hyg; 2007 Dec; 77(6 Suppl):276-81. PubMed ID: 18165503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Statistical methodology for the evaluation of vaccine efficacy in a phase III multi-centre trial of the RTS, S/AS01 malaria vaccine in African children.
    Lievens M; Aponte JJ; Williamson J; Mmbando B; Mohamed A; Bejon P; Leach A
    Malar J; 2011 Aug; 10():222. PubMed ID: 21816030
    [TBL] [Abstract][Full Text] [Related]  

  • 8. What should vaccine developers ask? Simulation of the effectiveness of malaria vaccines.
    Penny MA; Maire N; Studer A; Schapira A; Smith TA
    PLoS One; 2008 Sep; 3(9):e3193. PubMed ID: 18784833
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Melanoma Vaccine--AVAX Technologies: DNP-VACC, M-Vax.
    BioDrugs; 2003; 17(1):69-72. PubMed ID: 12534322
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Future access to HIV vaccines. Report from a WHO-UNAIDS Consultation, Geneva, 2-3 October 2000.
    AIDS; 2001 May; 15(7):W27-44. PubMed ID: 11399975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of severe malaria in a multicenter, phase III, RTS, S/AS01 malaria candidate vaccine trial: case definition, standardization of data collection and patient care.
    Vekemans J; Marsh K; Greenwood B; Leach A; Kabore W; Soulanoudjingar S; Asante KP; Ansong D; Evans J; Sacarlal J; Bejon P; Kamthunzi P; Salim N; Njuguna P; Hamel MJ; Otieno W; Gesase S; Schellenberg D;
    Malar J; 2011 Aug; 10():221. PubMed ID: 21816031
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of phase 3 trial of RTS, S/AS01 malaria vaccine: The need for an alternative development plan.
    Mahmoudi S; Keshavarz H
    Hum Vaccin Immunother; 2017 Sep; 13(9):2098-2101. PubMed ID: 28272979
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Understanding protective immune mechanisms induced by malaria vaccines in the context of clinical trials.
    Dobaño C; Campo JJ
    Hum Vaccin; 2009 Aug; 5(8):562-5. PubMed ID: 19287202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Report of a consultation on the optimization of clinical challenge trials for evaluation of candidate blood stage malaria vaccines, 18-19 March 2009, Bethesda, MD, USA.
    Moorthy VS; Diggs C; Ferro S; Good MF; Herrera S; Hill AV; Imoukhuede EB; Kumar S; Loucq C; Marsh K; Ockenhouse CF; Richie TL; Sauerwein RW
    Vaccine; 2009 Sep; 27(42):5719-25. PubMed ID: 19654061
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The time-course of protection of the RTS,S vaccine against malaria infections and clinical disease.
    Penny MA; Pemberton-Ross P; Smith TA
    Malar J; 2015 Nov; 14():437. PubMed ID: 26537608
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical trials to estimate the efficacy of preventive interventions against malaria in paediatric populations: a methodological review.
    Moorthy VS; Reed Z; Smith PG
    Malar J; 2009 Feb; 8():23. PubMed ID: 19208236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The development of the RTS,S malaria vaccine candidate: challenges and lessons.
    Ballou WR
    Parasite Immunol; 2009 Sep; 31(9):492-500. PubMed ID: 19691554
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Malaria vaccine trials in pregnant women: An imperative without precedent.
    Healy SA; Fried M; Richie T; Bok K; Little M; August A; Riley L; Swamy GK; Wylie BJ; Menendez C; Muehlenbachs A; Doumbo O; Greenwood B; Billingsley PF; Hoffman SL; Duffy PE
    Vaccine; 2019 Feb; 37(6):763-770. PubMed ID: 30621913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RTS,S: Toward a first landmark on the Malaria Vaccine Technology Roadmap.
    Kaslow DC; Biernaux S
    Vaccine; 2015 Dec; 33(52):7425-32. PubMed ID: 26431982
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Priorities in research and development of vaccines against Plasmodium vivax malaria.
    Brown GV; Moorthy VS; Reed Z; Mendis K; Arévalo-Herrera M; Alonso P;
    Vaccine; 2009 Dec; 27(52):7228-35. PubMed ID: 19761835
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.